New brain scan agent could spot tumor recurrence vs. radiation damage

This first-in-human study will test a new radioactive imaging agent called MeFAMP to see if it can safely and accurately detect brain tumors using PET scans. The study includes 28 people: healthy volunteers and patients with recurrent high-grade glioma or brain metastases from other cancers. The goal is to measure safety, radiation exposure, and whether MeFAMP can tell the difference between active tumor and changes caused by prior radiation therapy.